Gvoke (glucagon) is a prescription drug that’s used to treat severely low blood sugar in certain people with diabetes. Gvoke comes as a liquid solution that’s given as an injection under the skin.

If you can become pregnant, it’s important to consider whether Gvoke is a safe choice for you. It’s not known whether Gvoke is safe to use during pregnancy. This drug hasn’t been studied extensively ...

Gvoke (glucagon) is a brand-name drug prescribed for extremely low blood sugar from diabetes in adults and some children. Gvoke comes as a subcutaneous injection that’s used as needed. Gvoke is ...

Xeris Pharmaceuticals, a specialty pharmaceutical company, is introducing Gvoke HypoPen (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...

The new Gvoke Kit formulation is available as a 1mg/0.2mL single-dose vial and syringe kit. Gvoke ® Kit is now available for the treatment of severe hypoglycemia in adult and pediatric patients with ...

Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch Easy to use: premixed and ready-to-go A reliable method of delivery: 99% of people were ...

Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...

Credit: Getty Images. The FDA has approved the new Gvoke® Kit formulation for the treatment of severe hypoglycemia in patients with diabetes 2 years of age and older. The Food and Drug Administration ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic patients ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

First concentrated, ready-to-dilute liquid glucagon available for diagnostic procedures SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc.® is pleased to announce the commercial launch ...